Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients

Mult Scler. 2016 Oct;22(11):1495-1498. doi: 10.1177/1352458515618020. Epub 2015 Nov 12.


We report two patients with relapsing remitting multiple sclerosis (RRMS) on interferon (IFN) beta-1a treatment for more than 7 years who developed pulmonary arterial hypertension (PAH). Patient 1 developed severe PAH requiring lung transplantation. Histology showed typical proliferative lesions including plexiform lesions consistent with PAH. Patient 2 ceased IFN beta-1a, and their symptoms stabilised. Both cases highlight IFN beta-1a treatment as a potential risk factor for PAH. PAH needs to be considered as a diagnosis in patients on long-term IFN beta-1a treatment who develop new-onset respiratory symptoms.

Keywords: Beta-interferon; interferon; multiple sclerosis; pulmonary arterial hypertension.

Publication types

  • Case Reports

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Deprescriptions
  • Female
  • Humans
  • Hypertension, Pulmonary / epidemiology*
  • Hypertension, Pulmonary / pathology
  • Hypertension, Pulmonary / surgery
  • Interferon beta-1a / therapeutic use*
  • Lung Transplantation
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Risk Factors


  • Adjuvants, Immunologic
  • Interferon beta-1a